Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.

PloS one - 1 Jan 2012

Chong Huihui, Yao Xue, Zhang Chao, Cai Lifeng, Cui Sheng, Wang Youchun, He Yuxian

Abstract excerpt

Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion inhibitor that can irreversibly conjugate to serum albumin. Previous studies demonstrated its in vivo long half-life and potent anti-HIV activity. Here, we focused to characterize its biophysical properties and evaluate its antiviral spectrum. In contrast to T20 (Enfuvirtide, Fuzeon), ABT was able to form a stable α-helical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to Biophysical Phenomena

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Enfuvirtide

Share to HIV Envelope Protein gp41

Share to HIV Fusion Inhibitors

Share to Maleimides

Share to Virus Internalization

Source

Open in PubMed Open full text

Identifiers

PMID: 22403678
DOI: 10.1371/journal.pone.0032599
PMCID: PMC3293837

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.PMID 22403678Read ↗

SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to EnfuvirtideSemantic proximity Read ↗

Biochemistry and Biophysics of HIV-1 gp41 - Membrane Interactions and Implications for HIV-1 Envelope Protein Mediated Viral-Cell Fusion and Fusion Inhibitor DesignSemantic proximity Read ↗

Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antiviralsSemantic proximity Read ↗

Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 – 2014)Semantic proximity Read ↗

Peptide-Based Inhibitors of the HIV Envelope Protein and Other Class I Viral Fusion ProteinsSemantic proximity Read ↗

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strainsSemantic proximity Read ↗

Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency VirusSemantic proximity Read ↗

Protein Design of an HIV-1 Entry InhibitorSemantic proximity Read ↗

Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and InhibitionSemantic proximity Read ↗

Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.Semantic proximity Read ↗

Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.Semantic proximity Read ↗

Design of Artificial C-Peptides as Potential Anti-HIV-1 Inhibitors Based on 6-HB Formation MechanismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.